Suppr超能文献

受体复合物中的变构受体-蛋白质相互作用能否成为癌症免疫治疗的一种分子机制?

Can Allosteric Receptor-Protein Interactions in Receptor Complexes Be a Molecular Mechanism Involved in Cancer Immune Therapy?

作者信息

Borroto-Escuela Dasiel O, Fuxe Kjell

机构信息

Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Department of Biomolecular Science, Section of Physiology, University of Urbino, Urbino, Italy.

出版信息

Front Endocrinol (Lausanne). 2019 Aug 20;10:574. doi: 10.3389/fendo.2019.00574. eCollection 2019.

Abstract

Based on the work in the Central Nervous System with discoveries of allosteric receptor-receptor interactions in homo- and heteroreceptor complexes representing a major integrative mechanism in synapses and extrasynaptic regions, it is proposed that a similar mechanism may exist in the immunological synapses. We discuss a putative additional molecular mechanism for the ability of the inhibitory T cell signaling proteins CTLA-4 and PD-1 and the adenosine A2AR to diminish T cell activation leading to enhancement of cancer development. We suggest that in the same immunological synapse involving T cells and antigen presenting cells multiple heteroreceptor complexes may participate and be in balance with each other. Their composition can vary between functional states and among different types of T cells. The T cell receptor (TCR) and its accelerators, strongly enhancing T cell activation, can be under inhibitory control by T cell signaling proteins CTLA4 and PD-1 and also the adenosine A2AR through inhibitory allosteric receptor-receptor interactions in different types of heteroreceptor complexes. As a result, inhibitory tumor induced immunosuppression can develop due to a dominance of the inhibitory signaling causing a brake on the TCR and/or its accelerator and the cancer immunotherapy becomes blocked.

摘要

基于在中枢神经系统的研究工作,发现同型和异型受体复合物中的变构受体-受体相互作用是突触和突触外区域的主要整合机制,因此提出免疫突触中可能存在类似机制。我们讨论了一种假定的额外分子机制,涉及抑制性T细胞信号蛋白CTLA-4和PD-1以及腺苷A2AR,它们能够减弱T细胞活化,从而导致癌症发展增强。我们认为,在涉及T细胞和抗原呈递细胞的同一免疫突触中,多个异型受体复合物可能参与其中并相互平衡。它们的组成在功能状态之间以及不同类型的T细胞之间可能有所不同。T细胞受体(TCR)及其促进剂能强烈增强T细胞活化,但可通过不同类型异型受体复合物中的抑制性变构受体-受体相互作用,受到T细胞信号蛋白CTLA4和PD-1以及腺苷A2AR的抑制性控制。结果,由于抑制性信号占主导,导致TCR和/或其促进剂受到抑制,从而产生抑制性肿瘤诱导的免疫抑制,癌症免疫疗法也因此受阻。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/771d/6710404/9ebc76d072dc/fendo-10-00574-g0001.jpg

相似文献

1
Can Allosteric Receptor-Protein Interactions in Receptor Complexes Be a Molecular Mechanism Involved in Cancer Immune Therapy?
Front Endocrinol (Lausanne). 2019 Aug 20;10:574. doi: 10.3389/fendo.2019.00574. eCollection 2019.
2
Glutamate heteroreceptor complexes in the brain.
Pharmacol Rep. 2018 Oct;70(5):936-950. doi: 10.1016/j.pharep.2018.04.002. Epub 2018 Apr 11.
3
Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease.
Front Cell Neurosci. 2017 Feb 21;11:37. doi: 10.3389/fncel.2017.00037. eCollection 2017.
4
Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation.
Front Neurosci. 2018 Feb 6;12:43. doi: 10.3389/fnins.2018.00043. eCollection 2018.
5
A2AR-D2R Heteroreceptor Complexes in Cocaine Reward and Addiction.
Trends Pharmacol Sci. 2018 Dec;39(12):1008-1020. doi: 10.1016/j.tips.2018.10.007. Epub 2018 Oct 29.

本文引用的文献

1
On the G Protein-Coupled Receptor Neuromodulation of the Claustrum.
Neurochem Res. 2020 Jan;45(1):5-15. doi: 10.1007/s11064-019-02822-4. Epub 2019 Jun 6.
2
Understanding receptor heteromerization and its allosteric integration of signals.
Neuropharmacology. 2019 Jul 1;152:1-3. doi: 10.1016/j.neuropharm.2019.05.001. Epub 2019 May 2.
3
Attenuation of Oxytocin and Serotonin 2A Receptor Signaling through Novel Heteroreceptor Formation.
ACS Chem Neurosci. 2019 Jul 17;10(7):3225-3240. doi: 10.1021/acschemneuro.8b00665. Epub 2019 May 8.
4
A2AR-D2R Heteroreceptor Complexes in Cocaine Reward and Addiction.
Trends Pharmacol Sci. 2018 Dec;39(12):1008-1020. doi: 10.1016/j.tips.2018.10.007. Epub 2018 Oct 29.
5
Mapping the Interface of a GPCR Dimer: A Structural Model of the A Adenosine and D Dopamine Receptor Heteromer.
Front Pharmacol. 2018 Aug 30;9:829. doi: 10.3389/fphar.2018.00829. eCollection 2018.
6
Cannabidiol skews biased agonism at cannabinoid CB and CB receptors with smaller effect in CB-CB heteroreceptor complexes.
Biochem Pharmacol. 2018 Nov;157:148-158. doi: 10.1016/j.bcp.2018.08.046. Epub 2018 Sep 6.
7
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.
8
Glutamate heteroreceptor complexes in the brain.
Pharmacol Rep. 2018 Oct;70(5):936-950. doi: 10.1016/j.pharep.2018.04.002. Epub 2018 Apr 11.
9
Cannabigerol Action at Cannabinoid CB and CB Receptors and at CB-CB Heteroreceptor Complexes.
Front Pharmacol. 2018 Jun 21;9:632. doi: 10.3389/fphar.2018.00632. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验